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1Abstract 
Objectives: To systematically identify the outcome measures and instruments used in clinical 
studies of polymyalgia rheumatica (PMR) and to evaluate evidence about their measurement 
properties.
Methods: Searches based on the MeSH term ‘polymyalgia rheumatica’ were carried out in 
five databases. Two researchers were involved in screening, data extraction and risk of bias 
assessment. Once outcomes and instruments used were identified and categorised, key 
instruments were selected for further review through a consensus process. Studies on 
measurement properties of these instruments were appraised against the COSMIN-
OMERACT (Outcome Measures in Rheumatology) checklist to determine the extent of 
evidence supporting their use in PMR. 
Results: 46 studies were included. In decreasing order of frequency, the most common 
outcomes (and instruments) used were: markers of systemic inflammation (ESR/CRP), pain 
(visual analogue scale (VAS)), stiffness (duration in minutes) and physical function 
(elevation of upper limbs).  Instruments selected for further evaluation were ESR, CRP, pain 
VAS, morning stiffness duration and Health Assessment Questionnaire. Five studies 
evaluated measurement properties of these instruments, but none met all of the COSMIN-
OMERACT checklist criteria.
Conclusion: Measurement of outcomes in studies of PMR lacks consistency. The critical 
patient-centred domain of physical function is poorly assessed.  None of the candidate 
instruments considered for inclusion in the core outcome set had high quality evidence, 
derived from populations with PMR, on their full range of measurement properties. Further 
studies are needed to determine whether these instruments are suitable for inclusion in a Core 
Outcome Measurement set for PMR. 
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1Introduction
Polymyalgia rheumatica (PMR) is the most common inflammatory rheumatic condition of 
older people(Crowson et al., 2011) and is characterised by proximal pain and stiffness, raised 
inflammatory markers and a therapeutic response to glucocorticoids(Salvarani, Cantini and 
Hunder, 2008). A recent UK study using the Clinical Practice Research Datalink found an 
annual incidence of 96 per 100000 people aged over 40, with incidence rising markedly with 
increasing age(Partington et al., 2018).   
Although it is common, PMR remains under-researched and there are many unanswered 
questions about its management(Dejaco et al., 2015).  A Core Outcome Measurement set of 
standardised instruments for use in clinical studies of PMR would make it easier to synthesise 
future research evidence.
In 2016, a core domain set (‘what’ to measure) was endorsed by the Outcome Measures in 
Rheumatology (OMERACT) group. This comprises pain, stiffness, physical function and 
systemic inflammation(Mackie et al., 2017).  We now need to establish ‘how’ to best 
measure these domains.  A previous systematic review(Duarte et al., 2015) found a wide 
range of instruments had been used but was limited in its search strategy and inclusion 
criteria and did not assess the quality of the evidence found.  Furthermore, no review of the 
evidence for measurement properties of instruments in PMR has been carried out. 
We therefore set out to systematically:
1) identify all of the outcome measures and instruments previously used in clinical studies of 
PMR
2) evaluate the literature on the measurement properties of selected instruments to determine 
whether they sufficiently met the OMERACT Filter 2.1 requirements for discriminative 
ability(Boers et al., 2019).
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1Materials and Methods
Protocol and registration
The review protocol was registered in Prospero, 
https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=80058 Registration 
number CRD42017080058.
Ethics Approval
No ethical approval was necessary for this systematic review. 
Eligibility criteria
Studies were eligible if they included patients with PMR and reported original quantitative 
data on outcomes of PMR. A range of study types including randomised controlled trials, 
other interventional trials, prospective cohort studies, case control studies and cross-sectional 
studies were eligible for inclusion.  Editorials, commentaries, review articles, case reports 
and letters were excluded.  
Studies evaluating measurement properties of an instrument in patients with PMR were 
included and tagged to identify them for the second part of the review process.  
Studies that considered patients with PMR and giant cell arteritis (GCA) as a single group 
(i.e. PMR specific data not available), diagnostic studies and studies that solely reported 
outcomes not pertaining directly to PMR (e.g. cardiovascular events in patients with PMR) 
were excluded. 
Information sources
Five databases (MEDLINE via OVID, CINAHL via EBSCO, Embase via HDAS, Web of 
Science and the Cochrane Library) were searched from inception until September 30th 2017. 
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1Clinical trials registries (ClinicalTrials.gov, ISCTRN and the EU Clinical Trials Register) 
were reviewed to track any unpublished studies.  Experts in the field were contacted to see if 
they were aware of any ongoing studies of relevance. 
Searches
The search strategy (Table 1) was developed by the lead author (HT) with advice from a 
specialist health librarian.  It was based on the MeSH term “polymyalgia rheumatica” and 
adapted for each database.  
Study selection
Identified studies were imported into Endnote X8 (https://endnote.com) and duplicates 
removed.  HT screened these titles and uploaded eligible studies to Covidence 
(https://www.covidence.org/home).  HT screened all abstracts and full texts against the 
inclusion and exclusion criteria, and each was independently screened by one other review 
author (CO, SM, CDM, CM or CH).  Disagreements were resolved by discussion and if 
needed, by consensus with a third reviewer (SH).  
Data collection
Data from all included studies were extracted by HT. A second review author (CO, SM, 
CDM, CM, CH or SH) checked the extracted data for each.  Extracted data comprised lead 
author, journal and year of publication, study design, setting, criteria used to define PMR, 
sample size, participant age and gender distribution, type of intervention, duration of follow 
up, outcomes measured, instruments used and key findings. 
Data extraction for the review of measurement properties was carried out independently by 
HT and CO.  The additional information extracted for studies of measurement properties 
comprised: measurement properties evaluated, methods used and findings in relation to the 
measurement properties. 
Risk of bias
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1To inform judgement of overall study quality, risk of bias was assessed using criteria from 
three domains of the Quality In Prognosis Studies (QUIPS) tool(Hayden et al., 2013);  
domains 1 (study participation), 2 (study attrition) and 4 (outcome measurement).  The other 
three domains of the QUIPS tool were not applied as they were not relevant to all study types 
in the review.  Additional relevant criteria from the Cochrane Risk of Bias tool(Higgins et al., 
2011) were applied to included randomised controlled trials (adequacy of the randomisation 
and blinding process and whether the groups were treated equally throughout). 
Risk of bias assessment was carried out at the same time as data extraction. Studies were 
categorised as high, moderate or low risk for each domain.  HT carried out this process with 
review by a second team member (CO, SM, CDM, CM, CH or SH).  Any disagreements 
were discussed, and consensus reached. 
The assessment of risk of bias for each study was used in critical judgement of the weight 
given to the study when deciding which outcome measures to take forwards for evaluation of 
their measurement properties. 
Strengths and limitations of studies of measurement properties were evaluated independently 
by HT and CO. Studies were assessed against the COSMIN-OMERACT Good Methods 
Checklist (Table 2) and given a rating to signify whether they should be used as evidence for 
each measurement property evaluated (red = no, do not use this as evidence, amber = some 
cautions but this will be used as evidence, green = yes, likely low risk of bias). Results of this 
assessment were discussed with the wider review team and used to inform overall judgement 
on whether there was sufficient evidence to support the use of the instrument in PMR. 
Planned methods of analysis
Outcomes and instruments were categorised according to the core domain set agreed by the 
OMERACT PMR Working Group in 2016 (Mackie et al., 2017).  Instruments measuring 
domains that were not in the core set were also collated to establish other constructs assessed 
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1in studies of PMR to inform the future research agenda.  A narrative review of the results was 
carried out.  
The findings and quality assessment of all studies on individual measurement properties of 
each selected instrument were tabulated.  This information was synthesised into an overall 
rating of the body of evidence for each measurement property of each instrument in PMR. 
Results 
Study selection
46 studies were selected for inclusion in the review (Figure 1). 
No additional studies meeting the eligibility criteria were identified from reference lists or 
through contacting experts in PMR. 
Eight on-going or unpublished studies were identified from clinical trials registries. 
Study characteristics
The 46 included studies were carried out between 1995 and 2017.  40 were carried out in 
Europe, five in North America and one in Japan.  Only one study recruited exclusively from 
primary care(Cawley et al., 2017). 
Study types: 
The most frequent study type was prospective cohort study (n=23), followed by randomised 
controlled trial (n=10).  There were five pilot efficacy / safety studies, three non-randomised, 
non-controlled intervention studies, three case series and two case control studies.  
Numbers of participants and follow up:
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1The sample size of individual studies ranged from four(Salvarani et al., 2003) to 652(Cawley 
et al., 2017)).  Aside from the study by Cawley et al., all studies had <150 participants.  In 
longitudinal studies, follow up duration ranged from four weeks to four years. 
Age and gender of participants:
Mean age ranged from 62 to 78 years and most studies (n=42) had more female than male 
participants. 
Criteria used for diagnosis:
A range of classification criteria were used to identify participants with PMR.  The most 
commonly used were the Healey(Healey, 1984) and Chuang(Chuang et al., 1982) criteria (9 
studies and 8 studies respectively). Five studies used the 2012 EULAR / ACR 
criteria(Dasgupta et al., 2012), six used Bird criteria(Bird et al., 1979) and six used Jones and 
Hazleman criteria(Jones and Hazleman, 1981).  12 studies used clinician diagnosis or a 
specified combination of clinical features. 
Risk of bias within studies
13/46 studies were judged to have low risk of bias using the study participation domain as a 
marker of overall risk of bias.  25 were judged to have a moderate risk of bias and 8 were 
judged to have a high risk of bias. The most common reasons for high risk of bias rating were 
inadequate information about the recruitment process / response rate and small sample size 
for the study design. 
Those judged to be at a low risk of bias did not measure noticeably different outcomes to 
studies where risk of bias was higher and ultimately therefore the rating did not significantly 
influence the decision on which outcome measures to evaluate further. 
Outcomes measured 
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1A summary of outcomes measured by domain is given in Table 3. 
18/46 studies measured an outcome representing each of the core OMERACT domains, of 
which only two were randomised controlled trials ((Di Munno et al., 1995) and (Kreiner and 
Galbo, 2010)). 
Laboratory markers of inflammation
Laboratory markers of inflammation were reported in 43/46 studies.  Most studies measured 
both ESR and CRP (n=32).  The five measuring only ESR were all from before the year 2000 
whereas the five measuring only CRP were all published after the year 2000.  
Pain
32/46 studies assessed pain.  The most common instrument used (n=29) was a pain severity 
visual analogue scale (VAS) but the anchor question was rarely stated. 
Stiffness 
28/46 studies included an assessment of stiffness. In 26 studies, duration of morning stiffness 
in minutes was recorded.  Four studies additionally assessed stiffness severity using either a 
VAS or NRS.
Physical function
22/46 studies assessed physical function, with eight of these using more than one measure of 
function. In 13 studies, the functional assessment was ‘elevation of the upper limbs’ on a 0-3 
scale, measured as part of the composite Polymyalgia Rheumatica Activity Score (PMR-
AS*(Leeb and Bird, 2004)).  12 studies used the Health Assessment Questionnaire 
(HAQ(Fries et al., 1980) in some form, either the HAQ-DI (n=9) or the mHAQ (n=3).  
Disease activity / global assessment 
Page 11 of 42
A
cc
ep
te
d 
A
rt
ic
le
Th
is 
ac
ce
pt
ed
 a
rti
cl
e 
is 
pr
ot
ec
te
d 
by
 c
op
yr
ig
ht
. A
ll 
rig
ht
s r
es
er
ve
d.
 www.jrheum.orgDownloaded on August 17, 2020 from 
113/46 studies recorded PMR-AS(Leeb and Bird, 2004).  Six studies that did not use the PMR-
AS included a physician global assessment VAS. Nine studies included some form of patient 
global assessment. The wording of the questions and the scales for the global VAS varied 
between studies. 
Imaging 
9/46 studies included a form of imaging in their outcome set.  In five of these, assessment of 
the utility of the imaging technique in PMR was part of the study’s aims. 
On-going or unpublished studies
Five of the ongoing / unpublished studies specified their outcomes. Whilst there were no new 
outcomes used amongst these, 3/5 measured fatigue and 2/5 measured stiffness severity as 
well as duration of morning stiffness, possibly suggesting a trend towards these factors being 
attributed greater importance. 
Evaluation of measurement properties
The OMERACT PMR-SIG, comprised of clinicians, researchers and patient partners, met in 
2018 to determine whether instruments mapping to the core domains had satisfied tests for 
domain match and feasibility and if they should continue through the remaining steps of the 
OMERACT 2.1 Filter.  This process has been described in detail in a previous 
publication(Owen et al., 2019).  Results from the first part of the review informed this 
discussion and the following instruments were selected for further evaluation: laboratory 
markers of inflammation – CRP and ESR, pain – VAS and NRS, stiffness – VAS and NRS 
and duration of morning stiffness, function – mHAQ and HAQ-DI. 
Five studies were identified, through the search strategy described, that evaluated 
measurement properties of these instruments.  Results of the appraisal of these studies are 
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1summarised in Table 4. Table 5 presents an overview of the quality of evidence that exists for 
each instrument. 
The standardised OMERACT Summary of Measurement Properties tables were also 
completed for each instrument and the example for pain VAS is available as supplementary 
information. 
Pain VAS 
No studies explicitly aimed to assess construct validity but the reporting of the change in pain 
VAS in response to treatment and the correlation between pain VAS and other instruments 
demonstrated in Leeb 2003(Leeb et al., 2003) and Matteson 2012(Matteson et al., 2012) can 
be taken as some evidence supporting the validity of this measure in assessing PMR-related 
pain.  However, neither study set out hypotheses about the expected relationship with other 
outcomes and the comparator measures used were either not themselves validated in PMR or 
measured a different construct altogether.  Both were rated red against the Good Methods 
Checklist. 
Responsiveness of the pain VAS was evaluated in two studies(Kalke, Mukerjee and 
Dasgupta, 2000; McCarthy et al., 2014).  Neither study stated hypotheses about the 
anticipated change in response to treatment or the magnitude of the anticipated effect size a 
priori and again, both were rated red for this measurement property. 
Test-retest reliability of a pain VAS was evaluated by Matteson et al.(Matteson et al., 2012). 
The methods were appropriate, and the result suggests good reliability but the small sample 
size (14) meant that this study was rated amber. 
The percentage minimal detectable change (MDC) for pain VAS was calculated in the same 
small sub-group in this study (n=14)(Matteson et al., 2012).  This was the only study looking 
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1at any thresholds of meaning for a pain VAS in PMR. The authors did not evaluate what a 
minimally important change might be for patients and the study was rated red for this 
measurement property too.  
Duration of morning stiffness
The four studies that evaluated measurement properties of pain VAS all also evaluated 
duration of morning stiffness(Dasgupta, Matteson and Maradit-Kremers, no date; Kalke, 
Mukerjee and Dasgupta, 2000; Leeb et al., 2003; McCarthy et al., 2014).  The limitations to 
the methods discussed above also applied for this outcome measure and test-retest reliability 
was poorer. All were rated red for all measurement properties.
HAQ-DI
Kalke et al.(Kalke, Mukerjee and Dasgupta, 2000) evaluated the construct validity and 
responsiveness of the HAQ as an assessment of function in PMR but significant limitations 
meant it was rated red for both measurement properties.
Construct validity was evaluated by studying correlation of the HAQ with duration of 
morning stiffness, pain VAS and CRP, none of which are measures of function. The 
correlation was good (>0.6 in each case) but no hypotheses about the magnitude of change or 
strength of correlation were stated. Responsiveness was evaluated using the standardised 
response mean (SRM).  The SRM was higher for the HAQ than for the other measures in this 
study, suggesting greater responsiveness to change but no a priori hypotheses were stated. 
mHAQ
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1Two studies evaluated the mHAQ, covering the full range of measurement properties 
between them(Matteson et al., 2012; McCarthy et al., 2014), but they were rated red for all 
measurement properties except test-retest reliability. 
Both studies provide some evidence towards the construct validity of the mHAQ through 
demonstrating its improvement in response to treatment(Matteson et al., 2012; McCarthy et 
al., 2014).  McCarthy et al. also demonstrated correlation of the mHAQ with other outcome 
measures(McCarthy et al., 2014) but the comparator measures were not measures of function. 
Responsiveness of the mHAQ was evaluated by McCarthy et al. using appropriate statistical 
methods but no hypothesis about the magnitude of change was given(McCarthy et al., 2014).  
 
Test-retest reliability of the mHAQ was evaluated by Matteson et al.(Matteson et al., 2012). 
The ICC was 0.72 but the small sample size prevented the study being rated 
green(OMERACT, 2019). The percentage minimal detectable change was calculated in the 
same study but there was limited information on the methods and no attempt to determine a 
minimally important difference to patients.
ESR/CRP 
Construct validity was supported by three studies(Leeb et al., 2003; Matteson et al., 2012; 
McCarthy et al., 2014), which all confirmed that ESR and CRP improved with treatment of 
PMR.  McCarthy et al. found moderate correlation between ESR/CRP and the 
mHAQ(McCarthy et al., 2014) but these instruments do not measure the same construct. 
None of the studies set out hypotheses about expected relationships and all three studies were 
rated red.  
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1Responsiveness was evaluated in two studies(Kalke, Mukerjee and Dasgupta, 2000; 
McCarthy et al., 2014) but neither set out hypotheses about magnitude of change a priori. 
One study(McCarthy et al., 2013) addressed thresholds of meaning for ESR and CRP was 
rated amber. This study found that CRP was superior to ESR in detecting active disease and 
disease remission. 
Discussion
We identified all of the outcome measures and instruments used to date in studies of PMR 
and categorised them using the PMR Core Domain Set endorsed by OMERACT in 2016.  
Results from the first part of the review informed the decision on which instruments to 
evaluate as candidates for inclusion in a core instrument set.  Only five studies evaluating 
measurement properties of candidate instruments in populations with PMR were identified.  
Crucially, none of the studies were rated ‘green’ for any of the measurement properties when 
assessed against the COSMIN-OMERACT good methods criteria. For pain VAS and the 
mHAQ there was one study of test-retest reliability which achieved amber and there was one 
study considering thresholds of meaning for ESR/CRP which was also rated amber. 
The majority of PMR studies included in this review were cohort studies, with only ten 
randomised controlled trials. Almost all had sample sizes of less than 150 participants.  We 
found that outcome measures used in studies of PMR varied widely and were often poorly 
defined.  This makes comparing results across studies very difficult and prevents synthesis of 
current data to improve the evidence base. 
Systemic inflammation was most frequently assessed of the four PMR core domains, 
followed by pain and stiffness. Physical function was least often measured. This contrasts 
with findings from qualitative studies where patients with PMR have highlighted disability 
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1and stiffness as having significant impact on their quality of life(Mackie et al., 2015; Twohig 
et al., 2015).  
Pain was the most commonly assessed patient-reported outcome with a VAS being the most 
frequently used measurement instrument.  However, as noted in previous reviews(Duarte et 
al., 2015; Huang and Castrejon, 2016), there is little consistency in the question and scales 
used or on the time frame being considered. Each measurement property of pain VAS has 
been evaluated in PMR but there is only sufficient evidence on its test-retest reliability. 
Stiffness was measured in 28/46 studies in this review.  Given that it is a cardinal symptom of 
PMR, this is notably low.  No studies evaluated a stiffness severity VAS despite the widely 
acknowledged limitations of ‘duration of morning stiffness’ as an outcome measure(Halls et 
al., 2014, 2017; Mackie et al., 2015). We did not find sufficient evidence for any 
measurement property of duration of morning stiffness to support its use in PMR. 
Physical function was assessed in the least consistent way of the core domains.  Most 
frequently it was measured as part of the PMR-AS, an overall assessment of disease activity 
which includes evaluation of ‘elevation of the upper limbs’ on a 0-3 scale.  This is a very 
limited assessment of overall function and is insufficient to represent this domain(Mackie et 
al., 2015; Twohig et al., 2015).  Therefore, the measurement properties of mHAQ and HAQ-
DI were reviewed.  We found that neither mHAQ nor HAQ-DI had high quality evidence to 
support its use as an outcome measure in PMR.  Since physical function is of prime 
importance to people’s daily lives, the failure to measure it in a meaningful, reliable way that 
allows comparison across studies of PMR needs addressing. 
Where inflammatory markers are used in studies of PMR, ESR and CRP are usually both 
measured.  In studies that chose one over the other, more recent studies tended to use CRP 
rather than ESR. ESR and CRP are used to evaluate many rheumatological conditions and are 
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1frequently incorporated into disease activity scores.  Certain properties of biomarkers, such as 
face validity and feasibility, are likely to be transferrable across conditions. However, 
properties such as responsiveness and test-retest reliability may vary between conditions and 
the limited evaluation in patients with PMR is therefore of note.  Indeed, up to 20% of people 
with PMR may have normal ESR or CRP before treatment; the relationship between these 
biomarkers and PMR disease activity is not straightforward(Cantini et al., 2000). 
A small number of studies measured domains that were outside of the core set but included in 
the ‘important’ or ‘research agenda’ list by the OMERACT 2016 group(Helliwell et al., 
2016).  These include fatigue, psychological impact and overall health status.  Although these 
constructs are heavily intertwined, with each other and with pain, stiffness and function, this 
may signify a gap in the core domain set. An overall measure of PMR-related quality of life 
could be of value in addressing this gap. 
Strengths and limitations
The exclusion of papers considering PMR and GCA as a single group is a potential source of 
bias.  However, the risk of bias from including participants with GCA is high and outweighs 
the small risk of having missed any outcome measure of relevance.  One exception to this 
rule was made in including two papers (arising from one study) by McCarthy et al., in which 
one participant out of 60 had biopsy-proven GCA as well as PMR(McCarthy et al., 2013, 
2014).  This decision was made by the team because there were so few studies on 
measurement properties of instruments in PMR that these two papers contributed 
substantially to the available data and it was felt that there was minimal risk of bias from one 
participant having a dual diagnosis. 
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1Assessment of risk of bias of included studies added value in this review as it had not been 
done previously.  This is a subjective process but was carried out using an established tool 
and verified by a second assessor. That only 13 of the 46 studies demonstrated low risk of 
bias shows the limitations of the evidence base in PMR and has implications for the ability to 
draw firm conclusions from this review. This highlights the need to identify high-quality, 
well-documented datasets from modern clinical studies of PMR for further evaluation of 
instrument properties, as well as the need for a Core Outcome Measurement Set 
incorporating the best-performing instruments in order to standardise secondary outcomes 
across future trials.  
Conclusions
Measurement of outcomes in studies of PMR lacks consistency. The critical patient-centred 
domain of physical function is the least frequently measured of the OMERACT core domains 
and when it is measured, is often assessed only by ability to elevate the upper limbs.  Overall, 
none of the candidate instruments considered for inclusion in the core outcome set had high 
quality evidence, from studies in populations with PMR, on their full range of measurement 
properties. This is in part because there are very few published instrument validation studies. 
We are planning further studies re-examining individual patient data to determine whether 
the selected instruments are suitable for a Core Outcome Measurement Set for PMR. 
Footnotes
*The PMR-AS is defined as  
CRP + MSTx0.1 + VASpain + VASphysician +EUL0-3  
(where CRP is C-reactive protein (mg/dL), MST is morning stiffness duration in minutes, VAS is visual 
analogue scale (possible range: 0-10) and EUL is elevation of the upper limbs (possible range: 0-3)).
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Table 1: Search strategy for OVID Medline
1. polymyalgia rheumatica.mp.  
2. Polymyalgia Rheumatica/   
3. rheumatic polymyalgia.mp  
4. polymyalgia arteritica.mp.  
5. forestier certonciny syndrome.mp.  
6. rheumatic myalgia.mp.  
7. rhizomelic pseudopolyarthritis.mp.  
8. polymyalgi*.mp.  
9 senile gout.mp.  
10 1 -9 combined with OR  
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Table 2: Quality criteria for each measurement property, taken from the COSMIN-
OMERACT Good Methods Checklist (27)
Measurement Property Quality criteria
Construct validity 
(hypothesis testing)
Clear description given of the construct measured by the comparator 
instrument
Measurement properties of the comparator instrument described and 
adequate
Design and statistical methods adequate for the hypothesis to be tested
Otherwise free of any important flaws
Test re-test reliability Patients stable in the interim period
Time interval appropriate
Test conditions similar for the measurements
Correct statistic used (intra-class correlation coefficient for continuous 
data, Kappa for dichotomous / ordinal / nominal scores)
Otherwise free of important flaws
Responsiveness 
(longitudinal construct 
validity)
Criteria for change considered an adequate gold standard or the 
construct for change is clear, either as a situation of change or an 
actual indicator of change
Measurement properties of the comparator standard described and 
adequate
Statistical methods appropriate for the testing situations:
 For comparison to gold standard – ROC, AUC, predicative 
values, sensitivity and specificity, correlation of change with 
external anchor
 For constructs – effect size, standardised response mean, 
correlation
Otherwise free of important flaws
Clinical trial 
discrimination
Time interval between testing stated and appropriate
A proportion of people were expected to change in one or both groups
A priori hypotheses stated regarding the anticipated mean differences 
in change scores between sub-groups (positive, negative or no change 
expected)
Statistical methods adequate for the hypotheses tested (relative 
efficiencies, pooled treatment effect sizes, standardised mean 
differences)
Otherwise free of important flaws
Thresholds of meaning Patient group similar to target population
Criterion (external anchor, benchmarks, comparable population) 
selected in a credible manner
Analysis done separately for improvement and deterioration or only in 
direction anticipated in the target application 
Page 31 of 42
A
cc
ep
te
d 
A
rt
ic
le
Th
is 
ac
ce
pt
ed
 a
rti
cl
e 
is 
pr
ot
ec
te
d 
by
 c
op
yr
ig
ht
. A
ll 
rig
ht
s r
es
er
ve
d.
 www.jrheum.orgDownloaded on August 17, 2020 from 
Multiple criteria used and results triangulated
Analysis includes either a Youden index threshold from ROC or 
another cut off on a ROC approach.  If a threshold approach was used, 
was it tested for diagnostic utility (sensitivity and specificity)?
Otherwise free of any flaws
ROC = receiver operating characteristic curve
AUC = area under the curve
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Table 3: Summary of outcomes measured by domain (OMERACT core set domains in 
bold)
Domain Number of 
studies assessing 
this domain
Most frequent 
instrument used 
(number of 
studies)
Other instruments used 
(number of studies)
Laboratory 
markers of 
inflammation
43 / 46 (93%) ESR / CRP (42) IL-6 (10)
Fibrinogen (6) 
TNF-alpha (1)
Pain 32 / 46 (70%) VAS (29) NRS (2)
Physician assessment of 
pain (1)
Pain site manikins (2)
Stiffness 28 / 46 (63%) Morning stiffness 
duration in minutes 
(26)
Stiffness severity VAS / 
NRS (4)
Physician assessment of 
stiffness (1)
Stiffness site manikins (2)
Physical function 22 / 46 (48%) Elevation of upper 
limbs on 0-3 scale 
(13)
HAQ (12)
SF-36 physical 
component (36) (3)
American Rheumatism 
Association functional 
class assessment (37) (1)
Global assessment / 
disease activity
21 / 46 (46%) PMR-AS (13) Physician global 
assessment (6)
Patient global assessment 
(9)
Imaging 9 / 46 (2%) Ultrasound (6) MRI (3)
FDG PET-CT (2)
Other:
Physical 
examination, 
presence of 
synovitis, fever or 
weight loss 
10
Number of relapses, 
duration of treatment 
or cumulative steroid 
dose
7
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Other blood 
parameters (e.g. 
FBC, HbA1c, ACTH 
/ cortisol)
17
Fatigue 6 VAS (4) NRS (1)
Time to onset of fatigue 
for daily chores (1)
Health status 5 Unspecified 
questionnaire / VAS 
(4)
Back to normal question 
(1)
Mood / anxiety 1 Generalised Anxiety 
Disorder-7 (GAD-7) 
(38) (1)
Patient Health 
Questionnaire-8 
(PHQ-8) (39) (1)
 
VAS = visual analogue scale
NRS = numeric rating scale
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Table 4: Critical appraisal of the studies of measurement properties of instruments considered for inclusion in the core outcome set
Instrument Measurement 
property
Studies Quality assessment Findings Rating
Leeb 2003 
(22)
Comparison made to pre-treatment levels and 
correlation between VAS pain and other 
instruments was assessed.
No a priori hypotheses about magnitude of 
change or strength of correlation with other 
instruments stated. 
The comparator instruments were not measuring 
the same construct and / or were not themselves 
validated in PMR. 
Highly significant improvement at W24 
compared to baseline.
VAS pain was highly correlated with other 
measures including ESR / CRP and duration of 
morning stiffness.
Multiple regression analysis with VAS pain as 
the dependent variable showed that it correlated 
with self-reported myalgia and elevation of the 
upper limbs.
RedConstruct validity
Matteson 
2012 (23)
Comparison made to pre-treatment levels
No a priori hypotheses about magnitude of 
change or correlation with other instruments 
stated. 
Statistically significant improvement between 
baseline and W1 and W1 and W4 but not 
between W4 and W26.
Red
McCarthy 
2014 (25)**
Situation of change clear – newly diagnosed, 
started on treatment. 
PMR-AS used as gold standard for assessment of 
remission – accepted as a validated measure. 
Statistical methods were appropriate but no 
hypotheses about magnitude of change were 
made.
SRM = 0.89
ESS = 0.96
RedResponsiveness
Kalke 2000 
(24)
Small sample size, n=18
Situation of change clear – newly diagnosed, 
started on treatment. 
Statistical methods are appropriate but no 
hypotheses about magnitude of change were 
made.
SRM = 1.7 Red
Pain VAS
Test-retest reliability Matteson 
2012 (23)
Small sample size, n=14
Patients were stable in the interim time period; 
the time period was appropriate and test 
Global pain ICC = 0.82 Amber
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conditions were stable. 
Statistical methods were appropriate (ICC)
Thresholds of 
meaning
Matteson 
2012 (23)
Patient group is sufficiently similar to target 
population
Not enough information on methods given. 
No attempt to calculate minimally important 
difference to patients 
SDD and % MDC = 28.9. Red
Leeb 2003 
(22)
Comparison made to pre-treatment levels
No a priori hypotheses about magnitude of 
change or strength of correlation with other 
instruments stated
Highly significant improvement at W24 
compared to baseline.
RedConstruct validity
Matteson 
2012 (23)
Comparison made to pre-treatment levels
No a priori hypotheses about magnitude of 
change or correlation with other instruments 
stated. 
Statistically significant improvement between 
baseline and W1 and W1 and W4 but not 
between W4 and W26.
Red
McCarthy 
2014 (25)
Situation of change clear in active group – newly 
diagnosed, started on treatment. 
PMR-AS used as gold standard for assessment of 
remission – accepted as a validated measure. 
Statistical methods were appropriate but no 
hypotheses about magnitude of change were 
made.
SRM = 0.89
ESS = 0.96
RedResponsiveness
Kalke 2000 
(24)
Small study, n = 18
Situation of change clear – newly diagnosed, 
started on treatment. 
Statistical methods are appropriate but no 
hypotheses about magnitude of change were 
made.
SRM = 1.7 Red
Duration of 
morning 
stiffness
Test-retest reliability Matteson 
2012 (23)
Small sample size, n=14
Patients were stable in the interim time period; 
ICC 0.11 Red
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the time period was appropriate and test 
conditions were stable. 
Statistical methods were appropriate (ICC)
Thresholds of 
meaning 
Matteson 
2012 (23)
Patient group is sufficiently similar to target 
population
Not enough information on methods given. 
No attempt to calculate minimally important 
difference to patients 
SDD = 231 
%MDC = 16.1
Red
Construct validity Kalke 2000 
(24)
Small sample size, n = 18
No clear description of the construct measured 
by the comparator instrument (not measures of 
function).
No a priori hypotheses about magnitude of 
change or correlation with other instruments 
stated.
Significant improvement in HAQ score 
between pre- and post-treatment measurements
Linear regression coefficient with duration MS, 
pain VAS and CRP was 0.66, 0.72 and 0.63 
respectively
RedHAQ-DI
Responsiveness Kalke 2000 
(24)
Small sample size, n = 18
Situation of change clear – newly diagnosed, 
started on treatment. 
Statistical methods are appropriate but no 
hypotheses about direction of change or strength 
of correlation between instruments were made.
SRM = 3 Red
Matteson 
2012 (23)
Each instrument was compared to its pre-
treatment levels
No a priori hypotheses about magnitude of 
change or correlation with other instruments 
stated. 
Statistically significant improvement at all 
measurement time points
RedmHAQ Construct validity
McCarthy 
2014 (25)
Each instrument was compared to its pre-
treatment levels.
Comparator measures were not evaluating the 
same construct.
Statistically significant improvement between 
W1 and W6 in the active group. 
Correlation coefficients between mHAQ and 
PMR-AS, ESR and CRP were 0.68, 0.45 and 
Red
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No a priori hypotheses about magnitude of 
change or correlation with other instruments 
stated.
0.39 respectively
Responsiveness McCarthy 
2014 (25)
Situation of change clear in active group – newly 
diagnosed, started on treatment. 
PMR-AS used as gold standard for assessment of 
remission – accepted as a validated measure. 
Statistical methods were appropriate but no 
hypotheses about magnitude of change were 
made.
SRM = 1.36
ESS = 1.65
Red
Test-retest reliability Matteson 
2012 (23)
Small sample size, n=14
Patients were stable in the interim time period; 
the time period was appropriate and test 
conditions were stable. 
Statistical methods were appropriate (ICC)
ICC = 0.72 Amber
Thresholds of 
meaning
Matteson 
2012 (23)
Patient group is sufficiently similar to target 
population
Not enough information on methods given. 
No attempt to calculate minimally important 
difference to patients 
SDD = 0.78
% MDC = 25.9
Red
Leeb 2003 
(22)
Each instrument was compared to its pre-
treatment levels and correlation between VAS 
pain and ESR / CRP was assessed.
No a priori hypotheses about magnitude of 
change or strength of correlation with other 
instruments stated. 
Highly significant improvement at W24 
compared to baseline.
RedESR / CRP Construct validity
Matteson 
2012 (23)
Each instrument was compared to its pre-
treatment levels
No a priori hypotheses about magnitude of 
Statistically significant improvement between 
baseline and W1 and W1 and W4 but not 
between W4 and W26.
Red
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change or correlation with other instruments 
stated. 
McCarthy 
2014 (25)
Each instrument was compared to its pre-
treatment levels.
Comparator instrument for correlation was the 
mHAQ which measures a different construct. 
No explicit a priori hypotheses about magnitude 
of change or correlation with other instruments 
stated 
Statistically significant improvement from W1 
to W6 in the active group
Correlation coefficient between mHAQ and 
ESR / CRP = 0.45 / 0.39
Red
Responsiveness McCarthy 
2014 (25)
Situation of change clear in active group – newly 
diagnosed, started on treatment. 
PMR-AS used as gold standard for assessment of 
remission – accepted as a validated measure. 
Statistical methods were appropriate but no 
hypotheses about magnitude of change were 
made.
ESR SRM / ESS = 1.2 / 1.15
CRP SRM / ES = 1.05 / 1.14
Red
Kalke 2000 
(24)
Small study, n=18
Situation of change clear – newly diagnosed, 
started on treatment. 
Statistical methods are appropriate but no 
hypotheses about magnitude of change were 
made.
CRP SRM 1.6 Red
Thresholds of 
meaning
McCarthy 
2013  (28)**
Appropriate patient group. 
Criteria for assessment of disease activity and 
definition of remission satisfactory.
Thresholds for ESR and CRP cut offs justified 
from the literature.
Statistical methods satisfactory but did not use 
multiple methods to triangulate findings.
Ability of ESR >40mm/h / CRP >6mg/l to 
detect active disease:
Values for ESR: sensitivity 92%, specificity 
66%, PPV 0.72, Likelihood ratio 2.8. 
Values for CRP:  sensitivity 100%, specificity 
70%, PPV 0.77, Likelihood ratio 3.33
Ability of ESR <20mm/h / CRP <6mg/l to 
detect disease remission:
Amber
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Values for ESR: sensitivity 43%, specificity 
75%, PPV 0.87, Likelihood ratio 1.7. 
Values for CRP:  sensitivity 58%, specificity 
67%, PPV 0.88, Likelihood ratio 2.04.
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Table 5: Summary of quality of evidence on measurement properties of outcome measurement instruments in PMR
Evaluation of evidence supporting use of this instrument in PMR
N/A = not evaluated, - = evaluated but insufficient evidence to support use in clinical studies, + = evaluated and some evidence to support 
use, ++ = good evidence to support use in clinical studies
Construct validity Test-retest reliability Responsiveness Thresholds of meaning
Pain VAS - + - -
Stiffness VAS N/A N/A N/A N/A
Duration of 
morning stiffness - - - -
HAQ-DI - N/A - N/A
mHAQ - + - -
ESR and CRP - N/A - +
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Figure 1: PRISMA diagram of study selection process
*Studies in this group included those that  examined outcomes such as rates of cardiovascular disease or 
fractures in PMR or that analysed biochemical markers involved in the pathogenesis of the disease
16222 references identified from 5 databases
 
 
 
13194 studies underwent title review
609 studies underwent abstract review 
90 studies assessed for full-text eligibility 
46 studies included 
3028 duplicates removed
12585 studies excluded 
519 studies excluded
44 studies excluded
16  Patient group not exclusively 
PMR
13  Outcomes not directly of PMR* 
10  Full text not available / not 
available in includable language
5  Not empirical data 
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